Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib with a light breakfast in advanced renal cell carcinoma
NL-OMON53521Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabozantinib in renal cell carcinoma (RCC) (2 arms), sponsored by Leiden University Medical Center. Started May 2023; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON53521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53521.